Under the terms of the settlement, Glaxo has agreed not to assert its patent against Cypress’s new alcohol-free formulation of its generic ranitidine oral syrup. Cypress expects to launch the product immediately upon receiving FDA approval. As a result of the settlement, the parties filed a stipulation to dismiss their patent litigation pending in the US District Court of New York.